A late-night hot spot on one of Melbourne's most famous laneways is back (with an ex-Bar Margaux chef at the helm)
European$$$$
On a corner Bourke Street site at the edge of Meyers Place, the aptly named Lane's Edge has long been a hot spot for late-night drinks, fried snacks and long-necks in one of Melbourne's most famous laneways. Now, a fresh renovation and rebrand has transformed the venue into a Eurocentric wine bar (complete with a heated courtyard) serving a succinct yet elevated food menu that focuses on share plates, plus a more extensive wine list spanning both local and European drops.
With chef Gary Dick (ex-Bar Margaux) at the helm of the new kitchen, expect snacky bites that range from antipasto plates and thick slices of fluffy focaccia (available for $5 a pop), to familiar twists on European appetisers like sour cream Pringles served as a vessel for scooping up warming salt cod brandade. Bar-hopping fuel is on the cards until late with several snacks (including hot chippies) available after the chefs clock off for the night.
Drinks-wise, find fancified spins on cocktail classics, plus a thoughtful wine list – made all the more approachable with every bottle available by the glass thanks to a Coravin wine preservation system.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Age
5 hours ago
- The Age
‘Foreign freeloading nations': Trump takes aim at drug companies in latest threat to PBS
Washington: US President Donald Trump has blamed 'foreign freeloading nations' for the high drug prices faced by Americans and told pharmaceutical firms to negotiate harder with other countries, in a new threat to programs such as Australia's Pharmaceutical Benefits Scheme. Trump issued letters to the bosses of 17 drug firms on Thursday (Friday AEST) demanding they extend 'most favoured nation' pricing to the US Medicaid scheme, and guarantee that pricing level for new drugs. It means other comparable, high-income nations could not be offered cheaper prices than the US. 'Domestic MFN pricing will require you, and all manufacturers, to negotiate harder with foreign freeloading nations,' Trump wrote in the letters. 'US trade policy will endeavour to support this. However, increased revenues abroad must be repatriated to lower drug prices for American patients and taxpayers through an explicit agreement with the United States.' The letters were sent to major drugmakers including Pfizer, Eli Lilly, AstraZeneca and Johnson & Johnson, and published on Trump's social media. Loading They did not mention Australia but referred to putting 'an end to the free ride of American innovation by European and other developed nations'. Under the PBS, Australians can buy life-saving drugs worth thousands of dollars for as little as $31.60 a script after the government negotiates with the drug company to secure a lower price based on buying in bulk. Trump's letter makes explicit instructions to drug firms to 'negotiate harder' and return those extra profits to American patients and taxpayers.
Sydney Morning Herald
5 hours ago
- Sydney Morning Herald
‘Foreign freeloading nations': Trump takes aim at drug companies in latest threat to PBS
Washington: US President Donald Trump has blamed 'foreign freeloading nations' for the high drug prices faced by Americans and told pharmaceutical firms to negotiate harder with other countries, in a new threat to programs such as Australia's Pharmaceutical Benefits Scheme. Trump issued letters to the bosses of 17 drug firms on Thursday (Friday AEST) demanding they extend 'most favoured nation' pricing to the US Medicaid scheme, and guarantee that pricing level for new drugs. It means other comparable, high-income nations could not be offered cheaper prices than the US. 'Domestic MFN pricing will require you, and all manufacturers, to negotiate harder with foreign freeloading nations,' Trump wrote in the letters. 'US trade policy will endeavour to support this. However, increased revenues abroad must be repatriated to lower drug prices for American patients and taxpayers through an explicit agreement with the United States.' The letters were sent to major drugmakers including Pfizer, Eli Lilly, AstraZeneca and Johnson & Johnson, and published on Trump's social media. Loading They did not mention Australia but referred to putting 'an end to the free ride of American innovation by European and other developed nations'. Under the PBS, Australians can buy life-saving drugs worth thousands of dollars for as little as $31.60 a script after the government negotiates with the drug company to secure a lower price based on buying in bulk. Trump's letter makes explicit instructions to drug firms to 'negotiate harder' and return those extra profits to American patients and taxpayers.
Herald Sun
15 hours ago
- Herald Sun
Harvest Tech posts 135% revenue growth
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Harvest Technology Group records 135% YoY increase in quarterly revenue Raises $970,000 through mix of debt and convertible note instruments Dual lists on Frankfurt Stock Exchange to broaden investor base Special Report: Harvest Technology Group has recorded a 135% YoY increase in quarterly revenue, reaching $1.1 million in Q4 FY25, with the company expecting to exceed $3.5 million in total revenue for the full year. Cash receipts for remote communications tech-solutions provider Harvest Technology Group (ASX:HTG) for the June quarter came in at $631,000 with net cash inflows of $127,000. Net operating cash outflows for the quarter totalled $662,000 including $570,000 in R&D, $205,000 in staff, $17,000 in sales and marketing, $371,000 in corporate and administration, $105,000 in interest and $25,000 in other costs. HTG strengthened its balance sheet during the quarter, raising $970,000 (before costs) through a mix of debt and convertible note instruments including: $450,000 in unsecured convertible notes launched on June 30; $130,000 in secured convertible notes launched on June 27; and $390,000 short-term loan from managing director. After quarter end, HTG received a further $530,000 in funding in July through additional convertible notes and another loan from the managing director. In June HTG said it was tracking one year ahead of its pathway-to-profit plan as it focused on achieving a positive EBITDA before July 2026. As of June 30, HTG had $723,000 cash. Listing on Frankfurt Stock Exchange In a significant step toward expanding its international presence, HTG listed its shares on the open market segment of the Frankfurt Stock Exchange in April 2025. The dual listing is expected to broaden the investor base and increase visibility across European capital markets, with the company already experiencing an increase in trading volumes across both exchanges. In other key developments during the June quarter, HTG appointed Hugh Bickerstaff as sales and marketing director and strategic advisor. Bickerstaff brings deep expertise in founding and scaling some of Australia's fastest-growing technology businesses and is an experienced mentor in the sector. Start of Project Neon and new customer wins HTG also started project Neon, an Edge AI-enabled solution aimed at improving real-time decision-making in remote environments. The company secured new customer wins including two subsea services clients, with initial hardware sales and software subscriptions scheduled to begin in Q1 FY26. Additionally, the company expanded deployments across an existing customer fleet, unlocking further hardware sales and an uplift in recurring revenue from software. HTG continued engagement with a European defence customer via its Australian channel partner and began deploying its Nodestream technology across a new uncrewed surface vessel fleet in the Middle East. Enhancements to Nodestream platform In a major product milestone, HTG successfully integrated its Autopilot and Nodestream systems into a single, IP-rated enclosure. The robust weatherproof design simplifies installation and reduces the equipment footprint for deployment on autonomous vehicles and maritime vessels. The company also delivered significant improvements to its Nodestream platform during the quarter including a doubling of available data channels from 10 to 20, enabling more data-intensive operations. Additionally, the user interface has been overhauled to provide a more intuitive and efficient user experience. A comprehensive user permissions framework was introduced in Nodestream Live, improving access control and collaboration across distributed teams. This article was developed in collaboration with Harvest Technology Group, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions. Originally published as Harvest Tech posts 135% quarterly revenue surge
